SUMMARY The effect of administration of 12*5 sg ethinyloestradiol to 10 female patients with active rheumatoid arthritis was investigated in a prospective double blind crossover study. Some improvement during oestrogen treatment was found in 30 m walking time, haemoglobin concentration, and thrombocytosis. Erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) deteriorated in both periods, but less in the oestrogen period. Grip strength improved during both periods. The number of swollen joints decreased, whereas the joint tenderness score increased during the oestrogen period.
Sex hormones are one of the influences on the course of rheumatoid arthritis. It is well known that rheumatoid arthritis has a higher incidence in women. The epidemiological evidence that contraceptive and non-contraceptive female sex hormones decrease the incidence of rheumatoid arthritis in women seems contradictory to this.' 2 In several models of experimental arthropathy in animals both oestrogenic and androgenic hormones modulate the severity of the arthritis.3 4 The effect of exogenous sex hormones on the activity of rheumatoid arthritis was studied 20 years ago. The results were conflicting,> 6 and this line of investigation was not explored further.
We have studied the effect of low doses of oestrogens on rheumatoid arthritis in a 24 week prospective double blind crossover study. Some improvement during oestrogen therapy was noted.
Patients and methods
Ten female patients with adult onset, seropositive, classical (American Rheumatism Association (ARA) criteria) rheumatoid arthritis were admitted to the study. They had active disease shown by at least three of the following characteristics: (a) tenderness of more than six joints; (b) swelling of more than three joints; (c) Ritchie Seven women were postmenopausal (last menstrual cycle more than one year previously) and three premenopausal. The latter were using nonhormonal contraceptive devices. The age range was 27-68 years with a mean of 55-9 years; the disease duration ranged from one to 35 years with a mean of 16-3 years. All patients were ARA functional class 2. The study design was approved by the Ethical Committee, and the patients gave their informed consent.
Patients were randomly allocated to one of two treatment groups; 12-5 ig ethinyloestradiol or placebo was given in three cycles of four weeks (three weeks treatment followed by one 'withdrawal' week), total 12 weeks. This was followed by 12 weeks on the alternative treatment. The three premenopausal women started their treatment on the fifth day of their menses. Afterwards it was known that six women had started with placebo and four with oestrogens.
Assessment included clinical evaluation and blood 777 tests at baseline, 12, and 24 weeks. Clinical evaluation was performed by the same investigator (JWJB) at the same time of day, and both investigator and patient were unaware of the assigned treatment. Clinical evaluation included joint tenderness score and swollen joints score, as described by Ritchie7; grip strength measured with the same sphygmomanometer cuff inflated to 30 mmHg, wrapped in a standard sleeve (average of three recordings for each hand); and 30 m walking time.
Blood tests included ESR (Westergren), CRP (nephelometric), haemoglobin concentration, and number of thrombocytes (both by the Coulter counter).
Compliance was measured by the concentration of sex hormone binding globulins (by ammonium sulphate precipitation8), which increases significantly during oestrogen treatment.
To assess a possible influence of oestrogen treatment the data obtained were analysed based on the percentage changes during 12 weeks treatment (oestrogens v placebo). Statistical differences were calculated by a signed rank test.
Results
Nine patients completed the study; one women stopped after 22 weeks because of abdominal discomfort due to ovarian cysts. Afterwards it was found that she was first treated with oestrogens and in the second period with placebo. Her data are included in the final assessment.
Two treatment periods were compared: the 'placebo' period (six women the first 12 weeks plus four women the second 12 weeks) and the 'oestrogen period (four women the first 12 weeks plus six women the second 12 weeks).
In Table 1 the mean values and standard errors of the mean of the relevant parameters are given separately at the start of the placebo and of the oestrogen treatment period. Disease activity, as measured by clinical and laboratory data, was similar at the start of both treatment periods. As there was a wide variety of disease activity in the individual patients the changes found are given as percentage changes during both treatment periods. These changes are shown in Table 2 . Some differences between the placebo and the oestrogen treatment periods were then found. Joint In contrast with SLE, in rheumatoid arthritis oestrogens seem to have a preventive effect on the incidence of the disease, as shown by epidemiological studies. In addition, there are suggestions that oestrogens can ameliorate disease activity; the disease improves during pregnancy,t2 in premenopausal women disease activity fluctuates with the menstrual cycle,t3 and the present study also suggests an ameliorating effect of oestrogens.
In this study we used a low dosage of oestrogens as there are possible risks during long term oestrogen treatment. In four women mild side effects were noted; it thus can be concluded that this low dosage of ethinyloestradiol was biologically active. As progesterone has also been implicated in immunomodulation14 we preferred not to use a combination preparation, to prevent confusion in interpretation. In fact four patient groups should be discerned: (a) the patients who were treated with placebo during the first 12 weeks or (b) during the second 12 weeks and (c) the patients who were treated with oestrogens during the first period or (d) during the second period. Unfortunately the number of patients was too small to assess these groups separately. This could bias the results by abating the possible differences.
The duration of the treatment periods was relatively short: 12 weeks. Usually disease modifying antirheumatic drugs have a delayed response, with a possible beneficial effect after more than three months. In our study some improvement had already been noted within three months. Of the eight parameters, five seemed to improve during oestrogen treatment and only one during the placebo period. In addition, two of the three parameters that did not improve during oestrogen treatment deteriorated more during the placebo period. This study in only 10 patients and during a short period suggests that further research in this direction might be fruitful.
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